NasdaqCM - Nasdaq Real Time Price USD

Sensei Biotherapeutics, Inc. (SNSE)

0.3152

+0.0127

+(4.20%)

At close: June 2 at 4:00:00 PM EDT

0.3272

+0.01

+(3.81%)

After hours: June 2 at 7:35:24 PM EDT

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “T

GlobeNewswire 27 days ago

SNSE
+4.20%
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeuti

GlobeNewswire last month

SNSE
+4.20%
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage

GlobeNewswire 2 months ago

SNSE
+4.20%
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 re

GlobeNewswire 2 months ago

SNSE
+4.20%
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

SNSE
+4.20%
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET. A webcast of Sensei’s presentation will be available in th

GlobeNewswire 3 months ago

SNSE
+4.20%
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sens

GlobeNewswire 4 months ago

SNSE
+4.20%
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery an

GlobeNewswire 6 months ago

SNSE
+4.20%
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for

GlobeNewswire 6 months ago

SNSE
+4.20%
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a

GlobeNewswire 6 months ago

SNSE
+4.20%
3 US Penny Stocks To Monitor In October 2024

As the major U.S. stock indexes hover near record levels, investors are keenly observing market movements and economic indicators for signs of stability and growth. Penny stocks, although an antiquated term, continue to capture interest by offering potential growth opportunities at lower price points. When these smaller or newer companies boast strong financial health and solid fundamentals, they present a unique chance to discover value in the market's less-traveled paths.

Simply Wall St. 7 months ago

VANI

RLMD

SNSE
+4.20%
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD. Presentation Detail

GlobeNewswire 8 months ago

SNSE
+4.20%
Sensei Biotherapeutics to Present at Upcoming Conferences

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024: H.C. Wainwright 26th Annual Global Investment ConferenceCorporate PresentationMonday, September 9, 2024, at 7:00 a.m. ET. Virtual and New York, NY 2024 Cantor Fitzgerald Global

GlobeNewswire 8 months ago

SNSE
+4.20%
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported

GlobeNewswire 9 months ago

SNSE
+4.20%

Performance Overview

Return	SNSE	S&P 500 (^GSPC)
YTD	-35.67%	+0.92%
1-Year	-57.41%	+12.48%
3-Year	-83.41%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

3 US Penny Stocks To Monitor In October 2024

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Performance Overview